Where is the live CopyMark page for USPTO serial 79019586?

The live record is at https://getcopymark.com/trademark/79019586. Use https://getcopymark.com/trademark/{serialNumber} for any 8-digit USPTO serial.

Who owns PHARMAKODEX?

According to the public USPTO record for serial number 79019586, the listed owner(s) include: Vectura Limited, Vectura Limited, PHARMAKODEX LIMITED, PHARMAKODEX LIMITED.

What is USPTO serial number 79019586?

Serial number 79019586 is the USPTO application identifier for the mark PHARMAKODEX. It is used to track examination, publication, and registration of this trademark.

Which trademark classes cover PHARMAKODEX?

The public record lists International Classes: 005, 042. Each class corresponds to categories of goods or services identified in the application or registration.

Trademark: PHARMAKODEX Serial# 79019586 | status 404; last event DENC | Trademark Info & Attorney Guidance

Q: What is the current status of PHARMAKODEX?

PHARMAKODEX (79019586) currently shows USPTO status code 404 on the public record. This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with PHARMAKODEX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner

Monitor this mark, or talk with CopyMark about this registration.

Trademark Monitoring

(312) 319-4460

Not the owner?

File a new U.S. trademark application, or speak with our attorneys.

Start a new application

(312) 319-4460

Owner

Goods and services

Class	Description	Status	First use
005	Pharmaceutical and veterinary preparations and substances for the treatment of or protection against infectious diseases, pain, inflammation, sepsis, alopecia and obesity, and for the treatment of or protection against viral, metabolic, musculoskeletal, cardiovascular, genitourinary, central nervous system, endocrinological, immunological, obstetrical, gynecological, oncological, respiratory, neurological, gastrointestinal, hormonal, dermatological and psychiatric related diseases and disorders, and skin and tissue repair preparations; pharmaceutical preparations for use in pediatric medicine for the treatment of or protection against infectious diseases, pain, inflammation, sepsis, alopecia and obesity, and for the treatment of or protection against viral, metabolic, musculoskeletal, cardiovascular, genitourinary, central nervous system, endocrinological, immunological, obstetrical, gynecological, oncological, respiratory, neurological, gastrointestinal, hormonal, dermatological and psychiatric related diseases and disorders, and skin and tissue repair preparations; pharmaceutical preparations for use in geriatric medicine for the treatment of or protection against infectious diseases, pain, inflammation, sepsis, alopecia and obesity, and for the treatment of or protection against viral, metabolic, musculoskeletal, cardiovascular, genitourinary, central nervous system, endocrinological, immunological, obstetrical, gynecological, oncological, respiratory, neurological, gastrointestinal, hormonal, dermatological and psychiatric related diseases and disorders,and skin and tissue repair preparations; pharmaceutical preparations for use in treating diseases of the central nervous system, namely pain, epilepsy and Alzheimer's; pharmaceutical preparations for use in the treatment of infectious diseases, namely antibiotics; pharmaceutical preparations for use in pediatric medicine for the treatment of or protection against infectious diseases, pain, inflammation, sepsis, alopecia and obesity, and for the treatment of or protection against viral, metabolic, musculoskeletal, cardiovascular, genitourinary, central nervous system, endocrinological, immunological, obstetrical, gynecological, oncological, respiratory, neurological, gastrointestinal, hormonal, dermatological and psychiatric related diseases and disorders, and skin and tissue repair preparations, all formulated for dermal and/or transdermal or oral delivery, and/or as dry powders	SECTION 71 - CANCELLED	—
042	Scientific research and technical consulting in the field of medicine and research in the field of medicine and design of medicines and medicine delivery systems relating thereto; and design of medicines and medicine delivery systems relating thereto; design and development of computer hardware and software	SECTION 71 - CANCELLED	—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Date	Code	Event	What it means
Dec 18, 2015	DENC	NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED	—
Dec 18, 2015	DETH	DEATH OF INTERNATIONAL REGISTRATION	—
Jun 6, 2015	INNT	TOTAL INVALIDATION PROCESSED BY THE IB	—
Apr 8, 2015	XXSS	GENERIC MADRID TRANSACTION SENT TO IB	—
Apr 8, 2015	XXCR	GENERIC MADRID TRANSACTION CREATED	—
Feb 13, 2015	NREP	NEW REPRESENTATIVE AT IB RECEIVED	—
Sep 30, 2014	INTR	TOTAL INVALIDATION OF REG EXT PROTECTION CREATED	—
Jan 31, 2014	C71T	CANCELLED SECTION 71	—
Sep 19, 2008	FINO	FINAL DECISION TRANSACTION PROCESSED BY IB	—
Nov 9, 2007	FICS	FINAL DISPOSITION NOTICE SENT TO IB	—
Nov 9, 2007	FIMP	FINAL DISPOSITION PROCESSED	—
Nov 6, 2007	FICR	FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB	—
Jun 26, 2007	R.PR	REGISTERED-PRINCIPAL REGISTER	Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
May 3, 2007	CHLD	CHANGE OF OWNER RECEIVED FROM IB	—
Apr 10, 2007	PUBO	PUBLISHED FOR OPPOSITION	Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 21, 2007	NPUB	NOTICE OF PUBLICATION	—
Feb 21, 2007	PREV	LAW OFFICE PUBLICATION REVIEW COMPLETED	—
Feb 20, 2007	ALIE	ASSIGNED TO LIE	—
Jan 15, 2007	CNSA	APPROVED FOR PUB - PRINCIPAL REGISTER	—
Jan 9, 2007	ACEC	AMENDMENT FROM APPLICANT ENTERED	—
Dec 5, 2006	CRFA	CORRESPONDENCE RECEIVED IN LAW OFFICE	—
Dec 5, 2006	MAIL	PAPER RECEIVED	—
Oct 18, 2006	CNFR	FINAL REFUSAL MAILED	A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Oct 18, 2006	CNFR	FINAL REFUSAL WRITTEN	A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Aug 31, 2006	ACEC	AMENDMENT FROM APPLICANT ENTERED	—
Aug 4, 2006	CRFA	CORRESPONDENCE RECEIVED IN LAW OFFICE	—
Aug 4, 2006	MAIL	PAPER RECEIVED	—
Feb 24, 2006	RFNP	REFUSAL PROCESSED BY IB	—
Feb 7, 2006	RFCS	NON-FINAL ACTION MAILED - REFUSAL SENT TO IB	—
Feb 7, 2006	RFRR	REFUSAL PROCESSED BY MPU	—
Feb 6, 2006	RFCR	NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW	—
Feb 5, 2006	CNRT	NON-FINAL ACTION WRITTEN	A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 3, 2006	DOCK	ASSIGNED TO EXAMINER	—
Feb 3, 2006	NWAP	NEW APPLICATION ENTERED	—
Feb 2, 2006	REPR	SN ASSIGNED FOR SECT 66A APPL FROM IB	—

PHARMAKODEX